書籍詳細

[1] 造血器腫瘍の診療総論

P.45 掲載の参考文献

• 1) Jennings CD, Foon KA: Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997, 90:2863-2892.

• 2) van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
  pubmed

• 3) Campana D: Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003, 121:823-838.
  pubmed

• 4) Group JCO: National Cancer Institute Common Toxicity Criteria (NCI-CTC Version 2.0, April 30, 1999). http://www.jcog.jp/SHIRYOU/CTCJ_v20revised2001_09.pdf

• 5) Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
  pubmed

• 6) Handbook of Cancer Chemotherapy. (ed. 5th edition), (Skeel RT ed. ).

• 7) Ratain MJ: Pharmacology of Cancer Chemotherapy. (ed. 6th Edition), (Devita VT, Hellman S, Rosenberg SA, eds. ). Chapter 19. Principles and Practice of Oncotogy. Lippincott Williams & Wilkins, 2001.

• 8) O'Grady NP, Barie PS, Bartlett JG et al.: Practice guidelines for evaluating new fever incritically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis 1998, 26:1042-1059.

• 9) Weinstein MP: Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996, 23:40-46.
  pubmed

• 10) Mermel LA, Farr BM, Sherertz RJ et al.: Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1272.
  pubmed

• 11) Kami M, Fukui T, Ogawa S et al.: Use of real-time PCR on blood samples for diagnosis ofinvasive aspergillosis. Clin Infect Dis 2001, 33:1504-1512.

• 12) Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M: Invasivepulmonary aspergillosis. MRL CT, and plain radiographic findings and their contribution for early diagnosis. Chest 1994, 106:1156-1161.

• 13) Kanda Y, Chiba S, Hirai H et al.: Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003, 102:1541-1547.

• 14) Segal BH, Walsh TJ, Holland SM: Chapter 54: Infections in the Cancer Patient. (ed. 6th Edition), (Devita VT, Hellman S, Rosenberg SA, eds. ) Principles and Practice of Oncology. Lippincott Williams & Wilkins, 2001.

• 15) Dykewicz CA, Kaplan JE: Guidelines for preventing apportunistic infections among hematopoietic stem cell transplant recipients. http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf

• 16) Pizzo PA, Purvis DS, Waters C: Microbiological evaluation of food items. For patients undergoing gastrointestinal decontamination and protected isolation. J Am Diet Assoc 1982, 81:272-279.
  pubmed

• 17) Uzun O, Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995, 86:2063-2072.
  pubmed

• 18) Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998, 16:1179-1187.
  pubmed

• 19) Kanda Y, Kami M, Matsuyama T et al.: Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998, 16:33-37.
  pubmed

• 20) Slavin MA, Osborne B, Adams R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
  pubmed

• 21) Goodman JL, Winston DJ, Greenfield RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
  pubmed

• 22) Kanda Y, Yamamoto R, Chizuka A et al.: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials, Cancer 2000, 89:1611-1625.
  pubmed

• 23) Bunin NJ, Pui CH: Differing complications of hyperleukocytosis in children with acutelymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985, 3:1590-1595.
  pubmed

• 24) Sterner S, Plummer DW, Clinton J, Ruiz E: A comparison of the supraclavicular approach and the infraclavicular approach for subclavian vein catheterization. Ann Emerg Med 1986, 15:421-424.

• 25) Hughes WT, Armstrong D, Bodey GP et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
  pubmed

• 26) Hughes WT, Armstrong D, Bodey GP et al.: 1997 guidelines for the use of antimicrobialagents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997, 25:551-573.

• 27) Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993, 328:1323-1332.
  pubmed

• 28) EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668-672.
  pubmed

• 29) Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101-111.
  pubmed

• 30) Eriksson U, Seifert B, Schaffner A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Bmj 2001, 322:579-582.
  pubmed

• 31) Llanos A, CiezaJ, Bernardo J et al.: Effect of salt supplementation on amphotericin Bnephrotoxicity. Kidney Int 1991, 40:302-308.
  pubmed

• 32) Walsh TJ, Finberg RW, Arndt C et al.: Liposomal amphotericin B for empirical therapyin patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.

• 33) Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282-289.
  pubmed

• 34) Malik IA, Moid I, Aziz Z, Khan S, Suleman M: A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998, 105:478-483.

• 35) Boogaerts M, Winston DJ, Bow EJ et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistentfever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-422.
  pubmed

• 36) Herbrecht R, Denning DW, Patterson TF et al.: Voriconazole versus amphotericin B forprimary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.

• 37) Kanda Y, Mineishi S, Saito T et al.: Pre-emptive therapy against cytomegalovirus (CMV)disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001, 27:437-444.
  pubmed

• 38) Lipschik GY, Gill VJ, Lundgren JD et al.: Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992, 340:203-206,
  pubmed

• 39) Munoz L, Balmana J, Martino R, Sureda A, Rabella N, Brunet S: Abdominal pain as the initial symptom of visceral varicella zoster infection in hematopoietic stem cell transplant recipients, Med Clin (Barc)1998, 111:19-22.

• 40) Vento S, Cainelli F, Longhi MS: Reactivation of replication of hepatitis B and C Viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002, 3:333-340.

• 41) Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL: Lamivudine for the treatment ofhepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphonla. Br J Haematol 2002, 116:166-169.

• 42) Petros WP: Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy 1992, 12:32S-38S.
  pubmed

• 43) Hartmann LC, Tschetter LK, Habermann TM et al.: Granulocyte colony-stimulating factorin severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997, 336:1776-1780.

• 44) Pui CH, Boyett JM, Hughes WT et al.: Human granulocyte colony-stimulating factor afterinduction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997, 336:1781-1787.

• 45) Ozer H, Armitage JO, Bennett CL et al.: 2000 update of recomnlendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncoiogy Growth Factors Expert Panel. J Clin Oncol 2000, 18:3558-3585.

• 46) Kitagawa H, Chang II, Fujita T: Hyperkalemia due to nafamostat nlesylate. N Engl J Med 1995, 332:687.

• 47) Avvisati G, ten Cate JW, Buller HR, Mandelli F: Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989, 2:122-124.
  pubmed

• 48) Rebulla P, Finazzi G, Marangoni F et al.: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997, 337:1870-1875.

• 49) Evidence-based medicine. A new approach to teachingthe practice of medicine. Evidence-Based Medicine Working Group. JAMA 1992, 268:2420-2425.

• 50) Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn't. Bmj 1996, 312:71-72.

• 51) Evidence Based cardiology. (ed. 2nd Edition). (Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ eds. )

[2] 急性白血病の診療

P.88 掲載の参考文献

• 1) Bennett JM, Catovsky D, Daniel MT et al.: Proposals for the classification of the acuteleukaelnias. French-Anlerican-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
  pubmed

• 2) Lithotripsy, Health and Public Policy Committee, Anlerican College of Physicians. Ann Intern Med 1985, 103:626-629.
  pubmed

• 3) Bennett JM, Catovsky D, Daniel MT et al.: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991, 78:325-329.

• 4) Bennett JM, Catovsky D, Daniel MT et al.: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-Arnerican-British Cooperative Group. Ann Intern Med 1985, 103:460-462.
  pubmed

• 5) Garand R, Duchayne E, Blanchard D et al.: Minilnally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Francais d'Hematologie Cellulaire. Br J Haematol 1995, 90:868-875.
  pubmed

• 6) Morphologic, immunologic, and cytogenetic (MIC)working classification of acute lymphoblastic leukemias. Report of the workshop held in Leuven, Belgium, April 22-23, 1985, First MIC Cooperative Study Group. Cancer Genet Cytogenet 1986, 23:189-197.

• 7) Second MIC Cooperative Study Group: Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Report of the Workshop held in Leuven, Belgium, September 15-17, 1986, Cancer Genet Cytogenet 1988, 30:1-15.

• 8) Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997, 90:2969-2977.
  pubmed

• 9) Jennings CD, Foon KA: Recent advances in flow cytonletry: application to the diagnosis of hematologic malignancy. Blood 1997, 90:2863-2892.

• 10) Champlin R, Gale RP: Acute myelogenous leukemia: recent advances in therapy. Blood 1987, 69:1551-1562.
  pubmed

• 11) Kobayashi T, Miyawaki S, Tanimoto M et al.: Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996, 14:204-213.

• 12) Bishop JF, Matthews JP, Young GA et al.: A randomized study of high-dose cytarabine ininduction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
  pubmed

• 13) Weick JK, Kopecky KJ, Appelbaum FR et al.: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996, 88:2841-2851.

• 14) Mayer RJ, Davis RB, Schiffer CA et al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia, Cancer and Leukemia Group B. N Engl J Med 1994, 331:896-903.

• 15) Bloomfield CD, Lawrence D, Byrd JC et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
  pubmed

• 16) Berman E, Heller G, Santorsa J et al.: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patientswith newly diagnosed acute myelogenous leukemia. Blood 1991, 77:1666-1674.

• 17) Wiernik PH, Banks PL, Case DC, Jr et al.: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acutemyeloid leukemia. Blood 1992, 79:313-319.
  pubmed

• 18) Vogler WR, Velez-Garcia E, Weiner RS et al.: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia:a South-eastern Cancer Study Group Study. J Clin Oncol 1992, 10:1103-1111.

• 19) A systematic collaborative overview of randomized trials comparing idarubicin withdaunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haemalatol 1998, 103:100-109.
  pubmed

• 20) Zittoun RA, Mandelli F, Willemze R et al.: Autologous or allogeneic bone marrow translantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment or Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'AdUltO (GIMEMA) LeUkemia Cooperative Groups. N Engl J Med 1995, 332:217-223.

• 21) Reiffers J, Stoppa AM, Attal M et al.: Allogeneic vs autologous stem cell transplantation vs chelnotherapy in patients with acute myeloid leukemia in first remission:the BGMT 87 study. Leukemia 1996, 10:1874-1882.
  pubmed

• 22) Harousseau JL, Cahn JY, Pignon B et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) . Blood 1997, 90:2978-2986.
  pubmed

• 23) Burnett AK, Goldstone AH, Stevens RM et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission:results of MRC AML 10trial. UK Medical Research CouncilAdult and Children's Leukaemia Working Parties. Lancet 1998, 351:700-708.

• 24) Cassileth PA, Harrington DP, Appelbaum FR et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
  pubmed

• 25) Burnett AK, Wheatley K, Goldstone AHet al.: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002, 1 18:385-400.

• 26) Suciu S, Mandelli F, de Witte T et al.: Allogeneic compared with autologous stem celltransplantation in the treatment of patients younger than 46 years with acute nlyeloidleukemia (AML) in first complete remission (CR1) :an intention-to-treat analysis of theEORTC/GIMEMAAML-10 trial. Blood 2003, 102:1232-1240.

• 27) Gondo H, Harada M, Miyamoto T et al.: Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997, 20:821-826.
  pubmed

• 28) Morishima Y, Kodera Y, Ilirabayashi N et al.: Low incidence of acute GVIID in patientstransplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995, 15:235-239.

• 29) Morishima Y, Morishita Y, Tanimoto M et al.: Low incidence of acute graft-versus-hostdisease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatiblesiblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989, 74:2252-2256.

• 30) Ohno R, Kobayashi T, Tanimoto M et al.: Randomized study of individualized inductiontherapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of theJapan Adult Leukemia Study Group. Cancer 1993, 71:3888-3895.

• 31) Miyawaki S, Tanimoto M, Kobayashi T et al.: No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemial the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999, 70:97-104.

• 32) Robles C, Kim KM, Oken MMet al.:Low-dose cytarabine maintenance therapy vs observation after remission induction in adVanced acute myeloid leUkemia: an Eastern Cooperative Oncology Group Trial (E5483) . Leukemia 2000, 14:1349-1353.

• 33) Buchner T, Urbanitz D, Hiddemann W et al.: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML) : two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3:1583-1589.
  pubmed

• 34) Elonen E, Almqvist A, Hanninen A et al.: Comparison between four and eight cycles ofintensive chemotherapy in adult acute myeloid leukemia:arandomized trial of the Finnish Leukemia Group. Leukemia 1998, 12:1041-1048.

• 35) Cassileth PA, Lynch E, Hines JD et al.: Varying intensity of postremission therapy in acute myeloid leukemia, Blood 1992, 79:1924-1930.
  pubmed

• 36) Slovak ML, Kopecky KJ, Cassileth PA et al.: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:aSouthwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083,

• 37) Grimwade D, Walker H, Oliver F et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.

• 38) Stone RM, Berg DT, George SL et al.: Granulocyte-macrophage colony-stimulating factorafter initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995, 332:1671-1677.

• 39) Dombret H, Chastang C, Fenaux P et al.: A controlled study of recombinant human granulocyte colony-stimulating factor inelderlypatients aftertreatmentforacutemyelogenous leukemia. AMLCooperative Study Group. N Engl J Med 1995, 332:1678-1683.

• 40) Lowenberg B, Zittoun R, Kerkhofs H et al.: On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute mlyeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989, 7:1268-1274.

• 41) Hiddemann W, Kern W, Schoch C et al.: Management of acute myeloid leukemia in elderly patients, J Clin Oncol 1999, 17:3569-3576.
  pubmed

• 42) Yanlada K, Furusawa S, Saito K et al.: Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995, 9:10-14,

• 43) List AF, Kopecky KJ, Willman CL et al.: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia:a Southwest Oncology Groupstudy. Blood 2001, 98:3212-3220.

• 44) Lowenberg B, van Putten W, Theobald M et al.: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukenlia, N Engl J Med 2003, 349:743-752.
  pubmed

• 45) Sievers EL, Larson RA, Stadtmauer EA et al.: Efficacy and sarety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-3254.

• 46) Estey EH, Thall PF, Giles FJ et al.: Gemtuzumab ozogamicin with or without interleukin 11in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside Blood 2002, 99:4343-4349.
  pubmed

• 47) Feinstein LC, Sandmaier BM, Hegenbart U et al.: Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute niyeloid leukaemiain first complete remission. Br J Haematol 2003, 120:281-288.

• 48) Bertz H, Potthoff K, Finke J: Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J CIin Oncol 2003 , 21:1480-1484.

• 49) Ohno R, Tomonaga M, Kobayashi T et al.: Effect of granulocyte colony-stimulating factorafter intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990, 323:871-877.
  pubmed

• 50) Kantarjian HM, Estey EH, Plunkett W et al.: Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986, 81:387-394.
  pubmed

• 51) Lejeune C, Tubiana N, GastautJA et al.: High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol 1990, 44:240-243.
  pubmed

• 52) Walters RS, Kantarjian HM, Keating MJ et al.: Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988, 62:677-682.
  pubmed

• 53) Hiddemann W, Kreutzmann H, StraifKet al.: High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987, 69:744-749.

• 54) Sauter C, Fehr J, Frick P, Gmuer J, Ilonegger H, Martz G: Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine andvinblastine (A-triple-V) . Eur J Cancer Clin Oncol 1982, 18:733-737.

• 55) Sanz MA, Bonanad S, Sanz GF, Martin G: Carboplatin and etoposide in acute myeloid leukemia. Leukemia 1994, 8:1599-1600.
  pubmed

• 56) Parker JE, Pagliuca A, Mijovic A et al.: Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatmentofpoor-risk myelodysplastic syndromes and acutemyeloid leukaemia. Br J Haematol 1997, 99:939-944.

• 57) Huang ME, Ye YC, Chen SR et al.: Use of all-trans retinoic acid in the treatment of acutepromyelocytic leukemia. Blood 1988, 72:567-572.
  pubmed

• 58) Warrell RP Jr, Frankel SR, Miller WH Jret al.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid) . N Engl J Med 1991, 324:1385-1393.

• 59) Tallman MS, Andersen JW, Schiffer CA et al.: All-trans-retinoic acid) in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
  pubmed

• 60) Warrell RP Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 1993, 329:17-189,

• 61) Evans GD, Grimwade DJ: Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999, 33:219-229.
  pubmed

• 62) Specchia G. Lo Coco F, Vignetti M et al.: Extramedullary involvement at relapse in acutepromyelocytic leukemia patients treated or not with all-trans retinoic acid:areport bythe Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001, 19:4023-4028.
  pubmed

• 63) Fenaux P, Chastang C, Chevret S et al.: A randomized comparison of all transretinoicacid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role ofmaintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94:1192-1200.

• 64) Nucifora G, Larson RA, Rowley JD:P ersistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993, 82:712-715.

• 65) Tallman MS, Nabhan C, FeusnerJH, Rowe JM: Acute pronlyelocytic leukemia: evolvingtherapeutic strategies. Blood 2002, 99:759-767.
  pubmed

• 66) Nabhan C, Mehta J, Tallman MS: The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 2001, 28:219-226.
  pubmed

• 67) Linker CA:Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003, 31:731-738.
  pubmed

• 68) Kanamaru A, Takemoto Y, Tanimoto M et al.: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia, Japan Adult Leukemia Study Group. Blood 1995, 85:1202-1206.

• 69) Shen ZX, Chen GQ, Ni JH et al.: Use of arsellic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : II. Clinical efficacy and pharmacokinetics in relapsedpatients. Blood 1997, 89:3354-3360.

• 70) Soignet SL, Maslak P, Wang ZG et al.: Complete renlission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348,
  pubmed

• 71) Kwong YL, Au WY, Chinl CS, Pang A, Suen C, Liang R: Arsenic trioxide-andidarubicin-induced remissions in relapsed acute promyelocytic leukaenlia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001, 66:274-279.

• 72) Raffoux E, Rousselot P, Poupon J et al.: Combined treatnlent with arsenic trioxide andall-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003, 21:2326-2334.

• 73) Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-615.
  pubmed

• 74) Copelan EA, McGllire EA: The biology and treatment of acute lymphoblastic leukenlia inadults. Blood 1995, 85:1151-1168.

• 75) Iloelzer D, Gokbuget N, Ottmann O et al.: Acute lymphoblastic leukenmia. Hematology 2002-Anlerican Society of Hematology Educational Book 2002, pl62-192.

• 76) Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983, 1:546-551

• 77) Rohatiner AZ, Bassan R, Battista R et al.: High dose cytosine arabinoside in the initialtreatnlentof adults with acute lynlphoblastic leukaenlia. Br J Cancer 1990, 62:454-458.
  pubmed

• 78) Hallbook H, Simonsson B, Ahlgren T et al.: Iligh-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol 2002, 118:748-754.

• 79) Todeschini G, Tecchio C, Meneghini V et al.: Estimated 6-year event free survival o f55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase H protocol based on high induction dose of daunorubicin. Leukemia 1998, 12:144-149.

• 80) Dekker AW, van't Veer MB, Sizoo W et al.: Intensive postrenlission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 1997, 15:476-482.

• 81) Reiter A, Schrappe M, Ludwig WD et al.: Chemotherapy in 998 unselected childhood acute lynlphoblastic leukenlia patients. Results and conchlsions of the multicenter trial ALL-BFM 86. Blood 1994, 84:3122-3133.
  pubmed

• 82) Schauer P, Arlin ZA, Mertelsmann R et al.: Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983, 1:462-470.

• 83) Hussein KK, Dahlberg S, Head D et al.: Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989, 73:57-63.
  pubmed

• 84) Larson RA, Dodge RK, Burns CP et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia:cancer and leukenliagroup B study 8811. Blood 1995, 85:2025-2037.
  pubmed

• 85) Fiere D, Lepage E, Sebban C et al.: Adult acute lynlphoblastic leukemia: a multicentricrandomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993, 11:1990-2001.

• 86) Thiebaut A, Vernant JP, Degos L et al.: Adult acute lynlphocytic leukemia study testingchemotherapy and autologous and allogeneic transplantation. A foUow-up report of theFrench protocol LALA 87. Hematol Oncol Clin North Am 2000, 14:1353-1366.
  pubmed

• 87) Sebban C, Lepage E, Vernant JP et al.:Allogeneic bone marrow transplantation in adult acute lymphoblastic leukenlia in first complete remission:a comparative study. French Group of Therapy of Adult Acute Lynlphoblastic Leukemia. J Clin Oncol 1994, 12:2580-2587.
  pubmed

• 88) Attal M, Blaise D, Marit G et al.: Consolidation treatment ofadult acute lynlphoblasticleukemia: a prospective, randomized trial comparing allogeneic versus autologous bonemarrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995, 86:1619-1628.

• 89) Tanimoto M, Miyawaki S, Ino T et al.: Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adultpatients with acutelymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG) . Int J Hematol 1998, 68:421-4291

• 90) Ueda T, Miyawaki S, Asou N et al.: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukenlia Study Group. Int J Hematol 1998, 68:279-289.

• 91) Takeuchi J, Kyo T, Naito K et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259-1266.
  pubmed

• 92) Dombret H, Gabert J, Boiron JM et al.: Outcome of treatment in adults with Philadelphiachromosome-positive acute lymphoblastic leukemia-results of the prospective multicenterLALA-94 trial. Blood 2002, 100:2357-2366.

• 93) Wassmann B, Pfeifer H, Scheuring U et al.: Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractoryPhiladelphia-positive acute lymphoblastic leukernia (Ph+ALL) . Leukenmia 2002, 16:2358-2365.
  pubmed

• 94) Ottmann OG, Druker BJ, Sawyers CL et al.: A phase 2 study of imatinib in patients withrelapsed or refractory Philadelphia chronosome-positive acute lymphoid leukemias. Blood 2002, 100:1965-1971.

• 95) Druker BJ, Sawyers CL, Kantarjian H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis or chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosonle. N Engl J Med 2001, 344:1038-1042.
  pubmed

• 96) Boissel N, Auclerc MF, Lheritier V et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774-780.
  pubmed

• 97) Annino L, Vegna ML, Camera A et al.: Treatment of adult acute lymphoblastic leukemia (ALL) : long-term follow-up of the GIMEMA ALL O288 randomized study. Blood 2002, 99:863-871.

• 98) Hoelzer D, Ludwig WD, Thiel E et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495-508.
  pubmed

• 99) Lee EJ, Petroni GR, Schiffer CA et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014-4022.
  pubmed

[3] リンパ腫の診療

P.112 掲載の参考文献

• 1) Streubel B, Lamprecht A, DierlammJet al.: T (14; 18) (q32; q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339.

• 2) Medeiros LJ, Carr J: Overview of the role of molecular methods in the diagnosis of malignant lymphomas, Arch Pathol Lab Med 1999, 123:1189-1207,

• 3) Abdel-Reheim FA, Edwards E, Arber DA: Utility of a rapid polymerase chain reaction panel for the detection of molecular changes in B-cell lymphoma. Arch Pathol Lab Med 1996, 120:357-363.

• 4) Greiner TC, Raffeld M, Lutz C et al.: Analysis of T cell receptor-gammagene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chainreaction products, Correlation with tumor-specific sequences, Am J Pathol 1995 , 146:46-55.

• 5) Theodorou I, Bigorgne C, Delfau MH et al.: VJ rearrangements of the TCR gamma locusin peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturinggradient gel electrophoresis. J pathol 1996 , 178:303-310.

• 6) Jaffe E, Harris N, Stein H et al.: Pathology and Genetics of Tumors of Hamatopoietic and Lymphoid Tissues. Lyon, IARC Press , 2001.

• 7) Lister TA, Crowther D, Sutcliffe SB et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting, J Clin Oncol 1989, 7:1630-1636,
  pubmed

• 8) Greene FL, Page DL, Fleming ID et al.: AJCC cancer staging manual 6th ed. Philadelphia, Springer-Verlag, 2002.

• 9) Shibolet O, Ilan Y, Gilhs S et al.: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigencarriers. Blood 2002, 100:391-396.

• 10) Yeo W, Chan PK, Zhong S et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients withidentification of risk factors. J Med Virol 2000, 62:299-307,
  pubmed

• 11) Cheng AL: Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996, 87:1202.
  pubmed

• 12) Silvestri F, Ermacora A, Sperotto A et al.: Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000, 108:394-396.
  pubmed

• 13) Otieno MW, Banura C, Katongole-Mbidde E et al.: Therapeutic challenges of AIDS-relatednon-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst 2002, 94:718-732.

• 14) Ratner L, Lee J, Tang S et al.: Chemotherapy for human immunodeficiency virusassociated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171-2178.

• 15) Little RF, Pittaluga S, Grant N et al.: Highly effective treatment of acquired immunodeficiency syndronle-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003, 101:4653-4659.
  pubmed

• 16) Cheson BD, Horning SJ, Coiffier B et al.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, NCI Sponsored International Working Group, J Clin Oncol 1999, 17:1244.

P.129 掲載の参考文献

• 1) Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16:2780-2795.

• 2) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
  pubmed

• 3) McKelvey EM, Gottlieb JA, Wilson HE et al.: Hydroxyldaunomycin(Adriamycin)combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484-1493.
  pubmed

• 4) Fisher RI, Hubbard SM, DeVita VT et al.: Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58:45-51,

• 5) Fisher RI, Gaynor ER, Dahlberg S et al.: Comparison of a standard regimen(CHOP)withthree intensive chemotherapy regimens for advanced non-Hodgkin's lymphonla. N Engl J Med 1993, 328:1002-1006.

• 6) Gordon LI, Andersen J, Colgan J et al.: Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase inan intergroup study. Cancer 1995, 75:865-873.

• 7) Shipp MA, Neuberg D, Janicek M et al.: High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma:a dose-finding pilot study. J Clin Oncol 1995, 13:2916-2923.
  pubmed

• 8) Blayney DW, LeBlanc ML, Grogan T et al.: Dose-intense chemotherapy every 2 weekswith dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group(SWOG 9349). J Clin Oncol 2003, 21:2466-2473.

• 9) Wunderlich A, Kloess M, Reiser M et al.: Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chenlotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's lymphoma Study Group(DSHNHL). Ann Oncol 2003, 14:881-893.

• 10) Bartlett NL, Petroni GR, Parker BA et al.: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide(CHOPE)chemotherapy for patients with diffuselymphoma:Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001, 92:207-217.

• 11) Wilson WH, Grossbard ML, Pittaluga S et al.: Dose-adjusted EPOCH chemotherapy foruntreated large B-cell lymphomas:apharmacodynamic approach with high efficacy. Blood 2002, 99:2685-2693.

• 12) Gaynor ER, Unger JM, Miller TP et al.: Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol 2001, 19:750-755.
  pubmed

• 13) Sparano JA, Weller E, Nazeer T et al.: Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkinlymphoma: an Eastern Cooperative Oncology Group trial(E3493). Blood 2002, 100:1634-1640.

• 14) Tilly H, Mounier N, Lederlin P et al.: Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma:the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2000, 18:1309-1315.

• 15) Coiffier B, Haioun C, Ketterer N et al.: Rituximab(anti-CD20 monoclonal antibody)for the treatment of patients with relapsing or refractory aggressive lymphoma:arnulticenter phase II study. Blood 1998, 92:1927-1932.
  pubmed

• 16) Coiffier B, Lepage E, Briere J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 46:235-242.

• 17) Miller TP, Dahlberg S, CassadyJR et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998 , 339:21-26.
  pubmed

• 18) Miller TP, LeBlanc M, Spier C et al.: CHOP Alone Compared to CHOP Plus Radiotherapyfor Early Stage Aggressive Non-Hodgkin's Lymphomas:Update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood 2001, 98:724a.

• 19) Armitage JO, Cheson BD:Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988, 6:1335-1347.
  pubmed

• 20) Philip T, Guglielmi C, Hagenbeek A et al.: Autologousbone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
  pubmed

• 21) Rodriguez MA, Cabanillas FC, Velasquez W et al.: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995, 13:1734-1741,
  pubmed

• 22) Velasquez WS, McLaughlin P, Tucker S et al.: ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma:a 4-year follow-up study. J Clin Oncol 1994, 12:1169-1176.
  pubmed

• 23) Velasquez WS, Cabanillas F, Salvador P et al.: Effective salvage therapy for lymphomawith cisplatin in combination with high-dose Ara-C and dexamethasone(DHAP). Blood 1988, 71:117-122.

• 24) Press OW, Livingston R, Mortimer J et al.: Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991, 9:423-431

• 25) Cabanillas F, Hagemeister FB, McLaughlin P et al.: Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987, 5:407-412.

• 26) Gutierrez M, Chabner BA, Pearson D et al.: Role of a doxorubicin-containing regimen inrelapsed and resistant lymphomas:an 8-year follow-up study of EPOCH. J Clin Oncol 2000, 18:3633-3642,
  pubmed

• 27) Moskowitz CH, Bertino JR, Glassman JR et al.: Ifosfamide, carboplatin, and etoposide:a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3776-3785.
  pubmed

• 28) Colwill R, Crump M, Couture F et al.: Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995, 13:396-402.
  pubmed

• 29) Shipp MA, Abeloff MD, Antnlan KH et al.: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999, 17:423-429.

• 30) Blay J, Gomez F, Sebban C et al.: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse:analysis of the PARMA trial. Parma Group. Blood 1998, 92:3562-3568.
  pubmed

• 31) Hamlin PA, Zelenetz AD, Kewalramani T et al.: The age-adjusted international prognosticindex predicts autologous stem cell transplant(ASCT)outcome for patients with relapsedor primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.

• 32) Vose JM, Zhang MJ, Rowlings PA et al.: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission:a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001, 19:406-413.

• 33) Kewalramani T, Zelenetz AD, Iledrick EE et al.: High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma:an intention -to-treat analysis. Blood 2000, 96:2399-2304.

• 34) Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al.: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lyrnphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001, 93:22-30.
  pubmed

• 35) Haioun C, Lepage E, Gisselbrecht C et al.: Survival benefit of high-dose therapy inpoor-risk aggressive non-Hodgkin'slymphoma: Final analysis ofthe prospectiveLNH87-2 protocol-A groupe d'Etude des Lymphomas de I'Adulte Study. J Clin oncol 2000, 16:3025-3030.

• 36) Gisselbrecht C, Lepage E, Molina T et al.: Shortened first-line high-dose chemotherapyfor patients with poor-prognosisaggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.

• 37) Kaiser U, Uebelacker I, Abel U et al.: Randomized study to evaluate the use of high-dosetherapy as part of primary treatment for aggressive lymphoma. J Clin Oncol 2002, 20:4413-4419.

• 38) Taniguchi S, Yamasaki K, Ohno Y et al.: [Dose escalation study of high dose etoposide in autologous hematopoietic stem cell transplantation]. Rinsho Ketsueki 1993, 34:809-814.
  pubmed

• 39) Vose JM, Sharp G, Chan WC et al.: Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimalresidual disease. J Clin Oncol 2002, 20:2344-2352.

• 40) Itoh K, Ohtsu T, Sasaki Y et al, : Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim(glycosylated rHuG-CSF)in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group. Leuk Lymphoma 2000, 38:521-532.

• 41) Pavone V, Gaudio F, Guarini A et al.: Mobilization of peripheral blood stem cells withhigh-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29:285-290.
  pubmed

• 42) Watts MJ, Ings SJ, Leverett D et al.:ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g/m2 and G-CSF for pre-treated lymphoma patients:a matched pairs analysis of 78 patients. Br J Cancer 2000, 82:278-282.

• 43) Narayanasami U, Kanteti R, Morelli J et al.:Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of henlatopoietic progenitor cells for rescue inautologous transplantation. Blood 2001, 98:2059-2064.
  pubmed

• 44) Pedersen-Bjergaard J, Andersen MK, Christiansen DH:Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000, 95:3273-3279,
  pubmed

• 45) Darrington DL, Vose JM, Anderson JR et al.:Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994, 12:2527-2534.
  pubmed

• 46) Krishnan A, Bhatia S, Slovak ML et al.: Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma:an assessment of risk factors. Blood 2000, 95:1588-1593.
  pubmed

• 47) Friedberg JW, Neuberg D, Stone RM et al.: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3128-3135.
  pubmed

• 48) Armitage JO, Carbone PP, Connors JM et al.: Treatment-related myelodysplasia and acuteleukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003, 21:897-906,

• 49) Lillington DM, Micallef IN, Carpenter E et al.: Detection of chromosome abnormalitiespre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:2472-2481.

• 50) Metayer C, Curtis RE, Vose J et al.: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma:amulticenter case-control study. Blood 2003, 101:2015-2023.

• 51) Vose JM, Bierman PJ, Anderson JR et al.: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy:clinical course and patient followup. Blood 1992, 80:2142-2148.
  pubmed

• 52) Pan D, Moskowitz CH, Zelenetz AD et al.: Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation, Cancer J 2002, 8:371-376.
  pubmed

• 53) Branson K, Chopra R, Kottaridis PD et al.: Role of nonmyeloablative allogeneic stem-celltransplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031.

• 54) Longo DL, DeVita VT Jr, Duffey PL et al.: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma:results of a prospective randomized trial. J Clin Oncol 1991, 9 :25-38.

• 55) Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-celllymphoma. Ann Intern Med 1985, 102:596-602.

P.160 掲載の参考文献

• 1) Aisenberg AC: Problems in Hodgkin's disease management, Blood 1999, 93:761-777.
  pubmed

• 2) Linch DC et aL:Hodgkin's lymphoma:Choice of therapy and late complications. Educational Book, American Society of Hematology , 2000, 205-221.

• 3) Kuppers R et al.: Hodgkin disease: Ilodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derivedfrom B cells at various stages ofdevelopment. Proc Nat Acad Sci USA 1994, 91:10962-10966.

• 4) Specht L et al.: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease:A meta-analysis of 23 randomized trials involving 3888 patients, J Clin Oncol 1998, 16:830-884.

• 5) Canellos GP et al.: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, orMOPP alternating with ABVD, N Engl J Med 1992, 327:1478-1484.
  pubmed

• 6) Loeffler M et al.: Meta-analysis of chemotherapy versus combined treatment trials in Hodgkin's disease, J Clin Oncol 1998, 16:818-829.
  pubmed

• 7) Horning SJ et al.: Stanford V radiotherapy for locally extensive and advanced Hodgkin'sdisease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.

• 8) Diehl V et al.: Standard and increased-dose BEACOPP chemotherapy compared withCOPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
  pubmed

• 9) Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl JMed 1998, 339:1506-1514.

• 10) Linch DC et al.: Dose intensification with autologus bone marrow transplantation in relapsed and resistant Hodgkin's disease. Lancet 1993, 341:1051-1054,

• 11) Yuen AR et al.: Comparison between conventional salvage therapy and high-dose therapywith autografting for recurrent or refractory hodgkin's disease. Blood 1997, 89:814-822.
  pubmed

• 12) Schmitz N et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002, 359:2065-2071.
  pubmed

P.172 掲載の参考文献

• 1) Hoelzer D, Gokbuget N, Digel W et aL:Outcome of adult patients with T-lymphoblasticlymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379-4385.

• 2) Levine JE, Harris RE, Loberiza FR Jr et al.: Acomparison of allogeneic and autologousbone marrow transplantation for lymphoblastic lymphoma. Blood 2003, 101:2476-2482.

• 3) Howard OM, Gribben JG, Neuberg DS et al.: Rituximab and CHOP induction therapy fornewly diagnosed mantle-cell lymphoma:molecular complete responses are not predictiveof progression-free survival. J Clin Oncol 2002, 20:1288-1294.
  pubmed

• 4) Velders GA, Kluin-Nelemans JC, De Boer CJ et al.: Mantle-cell lymphoma:a population-based clinical study. J Clin Oncol 1996, 14:1269-1274.
  pubmed

• 5) Khouri IF, Romaguera J, Kantarjian H et al.: Hyper-CVAD and high-dosemethotrexate/cytarabine followed by stem-cell transplantation:an active regimen foraggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.

• 6) Lee EJ, Petroni GR, Schiffer CA et al.: Brief duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L 3 acute lymphocytic leukemia:results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014-4022.
  pubmed

• 7) Thomas DA, Cortes J, O'Brien S et al.: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461-2670.

• 8) Magrath I, Adde M, Shad A et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925-934.
  pubmed

• 9) Soussain C, Patte C, Ostronoff M et al.: Small noncleaved cell lymphoma and leukemia inadults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664-674.

• 10) van Besien K, Kelta M, Bahaguna P: Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001, 19:1855-1864.

• 11) Zinzani PL, Martelli M, Magagnoli M et al.: Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) Gallium scan in 50 patients. Blood 1999, 94:3289-3293.

• 12) Ferreri AJ, Abrey LE, Blay JY et al.: Summary statement on primary central nervoussystem lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12to 15, 2002. J Clin Oncol 2003, 21:2407-2414.

• 13) DeAngelis LM, Seiferheld W, Schold SC et al.:Combination chemotherapy and radiotherapy for primary central nervous system lymphoma:Radiation Therapy Oncology GroupStudy 93-10. J Clin Oncol 2002, 20:4643-4648.

• 14) Batchelor T, Carson K, O'Neill A et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy:a report of NABTT 96-07. J Clin Oncol 2003, 21 :1044-1049.
  pubmed

• 15) Rohatiner A, d'Amore F, Coiffier B et al.: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994, 5:397-400.
  pubmed

• 16) Du MQ, Isaccson PG: Gastric MALT lymphoma:from aetiology to treatment. Lancet Oncol 2002, 3:97-104.
  pubmed

• 17) Zucca E, Bertoni F, Roggero E et al.: The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000, 96:410-419.
  pubmed

• 18) Montalban C, Castrillo JM , Abraira V et al.: Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995, 6:355-362.
  pubmed

• 19) Schechter NR, Portlock CS, Yahalom J: Treatment of mucosa-associated lymphoid tissuelymphoma of the stomach with radiation alone. J Clin Oncol 1998, 16:1916-1921.
  pubmed

• 20) Stein H, Foss HD, Durkop H et al.:CD 30 (+) anaplastic large cell lynlphoma:a review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.

• 21) Fahni B, Pileri S, Zinzani PL et al.: ALK+lymphoma:clinico-pathological findings andoutcome. Blood 1999, 93:2697-2706.

• 22) Bekkenk MW, Geelen FA, van Voorst Vader PC et al.: Primary and secondary cutaneous CD 30 (+) lymphoproliferative disorders:a report from the Dutch CutaneousLymphoma Group on the long-term follow-up data of 219 patients and guidehnes for diagnosis and treatment. Blood 2000, 95:3653-3661.

• 23) Chan JK, Sin VC, Wong KF et al.: Nonnasal lymphoma expressing the natural killer cell marker CD 56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997, 89:4501-4513.

• 24) Liang R, Todd D, Chan TK et al.: Treatment outcome and prognostic factors for primarynasal lymphoma. J Clin Oncol 1995, 13:666-670.
  pubmed

• 25) Kim GE, Cho JH, Yang WI et al.: Angiocentric lymphoma of the head and neck:patternsof systemic failure after radiation treatment. J Clin Oncol 2000, 18:54-63.